Idenix, Janssen to jointly develop HCV combination therapies
The clinical development program includes Phase II studies evaluating IDX719, simeprevir (TMC435) and TMC647055 for the treatment of HCV after an initial drug-drug interaction study, expected to commence
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.